A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors

Trial Profile

A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Indoximod (Primary) ; Temozolomide (Primary)
  • Indications Brain cancer; Ependymoma; Glioma; Medulloblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 19 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 15 Oct 2015 Planned initiation date changed from 1 Sep 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
    • 21 Sep 2015 Treatment section revised.Initial dosing of Indoximod changed from 18.5 mg/kg/dose BID to 12.8 mg/kg/dose BID and planned escalation dose changed from 27.7 mg/kg/dose BID to 22.4 mg/kg/dose BID.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top